retatrutide efficacy clinical trials and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 retatrutide clinical trials safety efficacy

These effects form the foundation of incretin-based obesity therapy and have been studied extensively since semaglutides approval in 2017

Regulatory agencies like the FDA require strong safety databases for drugs that will be prescribed to millions of people, and a trial of this size provides the statistical power needed to detect both efficacy signals and uncommon adverse events

Foundayo is a once-daily pill classified as an oral small-molecule GLP-1 receptor agonist, with a different chemical structure from injectable GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and from oral semaglutide (Rybelsus, the Wegovy pill), which belongs to the same peptide class as the injectables

Some research suggests that GLP-1 receptor agonists may have protective effects on the gut lining

Excessive alcohol use is a known risk factor for pancreatitis

These symptoms can overlap with and potentially worsen the gastrointestinal effects already associated with GLP-1 therapy, making it difficult to distinguish which agent is responsible for adverse effects